Zurcher Kantonalbank Zurich Cantonalbank Raises Stock Position in DaVita Inc. (NYSE:DVA)

Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 22.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 114,166 shares of the company's stock after purchasing an additional 20,782 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.14% of DaVita worth $18,715,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of DVA. Assenagon Asset Management S.A. boosted its holdings in DaVita by 29.6% in the second quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company's stock worth $6,942,000 after purchasing an additional 11,454 shares during the last quarter. Comerica Bank boosted its stake in shares of DaVita by 41.4% in the 1st quarter. Comerica Bank now owns 34,431 shares of the company's stock worth $4,753,000 after buying an additional 10,074 shares during the last quarter. Quest Partners LLC bought a new stake in shares of DaVita in the third quarter worth $669,000. MBB Public Markets I LLC purchased a new stake in DaVita during the second quarter valued at $582,000. Finally, Chase Investment Counsel Corp lifted its holdings in DaVita by 56.3% in the third quarter. Chase Investment Counsel Corp now owns 33,084 shares of the company's stock valued at $5,423,000 after acquiring an additional 11,912 shares during the period. Institutional investors own 90.12% of the company's stock.

DaVita Price Performance

DaVita stock traded up $0.54 during mid-day trading on Friday, hitting $166.17. The stock had a trading volume of 314,276 shares, compared to its average volume of 821,067. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The firm's 50 day moving average is $158.57 and its 200 day moving average is $149.31. The firm has a market capitalization of $13.63 billion, a P/E ratio of 17.93, a P/E/G ratio of 0.93 and a beta of 0.89. DaVita Inc. has a one year low of $99.18 and a one year high of $169.51.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business had revenue of $3.26 billion for the quarter, compared to analysts' expectations of $3.25 billion. During the same quarter in the prior year, the business posted $2.85 EPS. The business's revenue for the quarter was up 4.6% compared to the same quarter last year. On average, sell-side analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Insider Transactions at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares of the company's stock, valued at approximately $138,284,666.75. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.00% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on DVA shares. Bank of America upped their price target on shares of DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a research report on Wednesday, August 7th. UBS Group lifted their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. Barclays raised their target price on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. Finally, Truist Financial boosted their price target on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, DaVita presently has an average rating of "Hold" and a consensus price target of $161.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.